for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Surface Oncology And Merck To Collaborate On Immuno-Oncology Study Evaluating Srf617, Targeting CD39 In Combination With Keytruda In Solid Tumor Patients

May 20 (Reuters) - Surface Oncology Inc:

* SURFACE ONCOLOGY AND MERCK TO COLLABORATE ON IMMUNO-ONCOLOGY STUDY EVALUATING SRF617, TARGETING CD39 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN SOLID TUMOR PATIENTS

* SURFACE ONCOLOGY INC - COMBINATION WILL BE STUDIED AS A COMPONENT OF FIRST-IN-HUMAN PHASE 1/1B STUDY OF SRF617 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up